Genelux Statistics
Total Valuation
Genelux has a market cap or net worth of $123.80 million. The enterprise value is $110.89 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genelux has 44.37 million shares outstanding. The number of shares has increased by 18.21% in one year.
| Current Share Class | 44.37M |
| Shares Outstanding | 44.37M |
| Shares Change (YoY) | +18.21% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 9.01% |
| Owned by Institutions (%) | 20.54% |
| Float | 36.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15,474.90 |
| Forward PS | n/a |
| PB Ratio | 9.11 |
| P/TBV Ratio | 10.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13,861.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.15.
| Current Ratio | 2.43 |
| Quick Ratio | 2.34 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -170.00% and return on invested capital (ROIC) is -100.35%.
| Return on Equity (ROE) | -170.00% |
| Return on Assets (ROA) | -77.25% |
| Return on Invested Capital (ROIC) | -100.35% |
| Return on Capital Employed (ROCE) | -259.44% |
| Weighted Average Cost of Capital (WACC) | 6.70% |
| Revenue Per Employee | $308 |
| Profits Per Employee | -$1.24M |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.56% in the last 52 weeks. The beta is 0.46, so Genelux's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +8.56% |
| 50-Day Moving Average | 2.62 |
| 200-Day Moving Average | 3.84 |
| Relative Strength Index (RSI) | 56.77 |
| Average Volume (20 Days) | 261,712 |
Short Selling Information
The latest short interest is 3.14 million, so 7.07% of the outstanding shares have been sold short.
| Short Interest | 3.14M |
| Short Previous Month | 2.85M |
| Short % of Shares Out | 7.07% |
| Short % of Float | 8.67% |
| Short Ratio (days to cover) | 17.03 |
Income Statement
In the last 12 months, Genelux had revenue of $8,000 and -$32.15 million in losses. Loss per share was -$0.86.
| Revenue | 8,000 |
| Gross Profit | 8,000 |
| Operating Income | -33.21M |
| Pretax Income | -32.15M |
| Net Income | -32.15M |
| EBITDA | -32.97M |
| EBIT | -33.21M |
| Loss Per Share | -$0.86 |
Full Income StatementBalance Sheet
The company has $14.60 million in cash and $1.69 million in debt, with a net cash position of $12.91 million or $0.29 per share.
| Cash & Cash Equivalents | 14.60M |
| Total Debt | 1.69M |
| Net Cash | 12.91M |
| Net Cash Per Share | $0.29 |
| Equity (Book Value) | 11.54M |
| Book Value Per Share | 0.31 |
| Working Capital | 8.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.27 million and capital expenditures -$1.10 million, giving a free cash flow of -$26.37 million.
| Operating Cash Flow | -25.27M |
| Capital Expenditures | -1.10M |
| Depreciation & Amortization | 244,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -26.37M |
| FCF Per Share | -$0.59 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -415,175.00% |
| Pretax Margin | -401,812.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genelux does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.21% |
| Shareholder Yield | -18.21% |
| Earnings Yield | -25.97% |
| FCF Yield | -21.30% |
Analyst Forecast
The average price target for Genelux is $17.25, which is 518.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.25 |
| Price Target Difference | 518.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 689.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genelux has an Altman Z-Score of -14.74 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.74 |
| Piotroski F-Score | 1 |
